KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Deferred Taxes (2016 - 2025)

Emergent BioSolutions' Deferred Taxes history spans 16 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 475.0% year-over-year to $1.5 million; the TTM value through Dec 2025 reached -$4.0 million, up 27.27%, while the annual FY2025 figure was -$4.0 million, 27.27% up from the prior year.
  • Deferred Taxes reached $1.5 million in Q4 2025 per EBS's latest filing, up from -$10.2 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $45.4 million in Q4 2021 to a low of -$54.1 million in Q4 2022.
  • Average Deferred Taxes over 5 years is -$50000.0, with a median of -$300000.0 recorded in 2024.
  • Peak YoY movement for Deferred Taxes: surged 4027.27% in 2021, then crashed 6850.0% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $45.4 million in 2021, then plummeted by 219.16% to -$54.1 million in 2022, then soared by 90.39% to -$5.2 million in 2023, then surged by 92.31% to -$400000.0 in 2024, then surged by 475.0% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Deferred Taxes are $1.5 million (Q4 2025), -$10.2 million (Q3 2025), and -$13.9 million (Q2 2025).